MedTrace Logo

German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00198978 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 377

Last updated 2023-03-20

No results posted yet for this study

Summary

The study evaluates the efficacy and tolerability of a dose-reduced chemotherapy for the treatment of elderly patients with acute lymphoblastic leukemia. In patients with expression of CD20 on leukemic cells the efficacy and tolerability of additional application of Rituximab together with chemotherapy is evaluated.

Conditions

  • Adult Acute Lymphocytic Leukemia

Interventions

DRUG

Cyclophosphamide

DRUG

Dexamethasone / Prednisolone

DRUG

Cytarabine

DRUG

Idarubicin

DRUG

Granulocyte-Colony-Stimulating Factor

DRUG

Mercaptopurine

DRUG

Methotrexate

DRUG

Rituximab

DRUG

HDARAC

DRUG

Vincristine

DRUG

Depocyte

DRUG

Asparaginase

Sponsors & Collaborators

  • Goethe University

    lead OTHER

Principal Investigators

  • Dieter Hoelzer, MD,PhD · University of Frankfurt, Medical Dept. II

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2011-06-30
Completion
2014-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00198978 on ClinicalTrials.gov